	US 11,673,962 B2
	Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
Cameron Durrant, Oxford, FL (US); and Dale Chappell, Nidwalden (CH)
Assigned to HUMANIGEN, INC., Short Hills, NJ (US)
Appl. No. 16/652,977
Filed by HUMANIGEN, INC., Short Hills, NJ (US)
PCT Filed Oct. 2, 2018, PCT No. PCT/US2018/053933 § 371(c)(1), (2) Date Apr. 1, 2020, PCT Pub. No. WO2019/070680, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/567,187, filed on Oct. 2, 2017.
Claims priority of provisional application 62/729,043, filed on Sep. 10, 2018.
Prior Publication US 2020/0354443 A1, Nov. 12, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01); C07K 14/535 (2006.01); A61P 43/00 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01)

CPC C07K 16/2893 (2013.01) [A61K 39/3955 (2013.01); A61P 43/00 (2018.01); C07K 14/535 (2013.01); C07K 16/243 (2013.01); C07K 16/2809 (2013.01); C07K 16/2887 (2013.01); A61K 35/17 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

16 Claims

1. A method of increasing the efficacy of CAR-T immunotherapy in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein the recombinant hGM-CSF antagonist is anti-hGM-CSF antibody lenzilumab, wherein said administering increases the efficacy of CAR-T immunotherapy in said subject.